scholarly journals Erratum: Effects of once-daily versus twice daily dosing of Calcium Fructoborate on knee discomfort. A 90 day, double-blind, placebo controlled randomized clinical study

2021 ◽  
pp. 1-1
Author(s):  
Z. Pietrzkowski ◽  
A. Roldán Mercado-Sesma ◽  
R. Argumedo ◽  
M. Cervantes ◽  
B. Nemzer ◽  
...  
Keyword(s):  
Clinical Study ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Randomized Clinical Study ◽  
Calcium Fructoborate

scholarly journals EFFECTS OF ONCE-DAILY VERSUS TWICE DAILY DOSING OF CALCIUM FRUCTOBORATE ON KNEE DISCOMFORT. A 90 DAY, DOUBLE-BLIND, PLACEBO CONTROLLED RANDOMIZED CLINICAL STUDY

2018 ◽  
pp. 1-6
Author(s):  
Z. Pietrzkowski ◽  
A. Roldán Mercado-Sesma ◽  
R. Argumedo ◽  
M. Cervantes ◽  
B. Nemzer ◽  
...  
Keyword(s):  
Randomized Study ◽  
Control Group ◽  
Mcgill Pain Questionnaire ◽  
Double Blind ◽  
Test Analysis ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Randomized Clinical Study ◽  
Supplementation Period ◽  
Calcium Fructoborate

Importance: Previous research showed that a twice-daily 108 mg dose of calcium fructoborate (CFB) improved knee discomfort during a 2-week supplementation period. This current double-blind, placebo-controlled randomized study investigates the effects of CFB supplementation on knee discomfort during 90 days of supplementation. Purpose: To evaluate the comparative effects of once-daily and twice-daily dosing of calcium fructoborate on knee joint discomfort for ninety days. Design: 120 participants with self-reported knee discomfort were recruited and randomized into three groups (each N=40). Participants received: 108 mg CFB twice per day (CFB-G1); or, 216 mg CFB in a single dose (CFB-G2); or, placebo. Setting: Subjects were recruited through advertisement in local papers. The researchers assessed intake and within-study levels of knee discomfort by using the McGill Pain Questionnaire (MPQ) and the Western Ontario and McMaster University Arthritis Index (WOMAC). Results: 62 female and 59 male subjects completed the study. Subjects’ average age was (52.84 ± 8.19 years) and average BMI was (26.76 ± 2.50 kg/m2). Statistical differences between groups were calculated using a two-sided, two-sample t-test. Analysis of variance (ANOVA) was used to estimate within-group changes in mean WOMAC and MPQ scores as well as against the control group. When compared to placebo, CFB-G1 showed a significant decrease in reported discomfort on day 14 (P=0.02,) day 30 (P=0.003), day 60 (P<0.0001) and day 90 (P<0.0001) according to WOMAC Scores. A similar decrease was observed for CFB-G2 WOMAC Scores on day 14 (P=0.02), day 30 (P=0.0003), day 60 (P<0.0001) and day 90 (P<0.0001). When compared to placebo, the MPQ score for CFB-G1 group decreased on day 7 (P=0.002), day 14 (P=0.001), day 30 (P<0.0001), day 60 (P<0.0001) and day 90 (P<0.0001). MPQ score decreases were also observed for CFB-G2 group on day 7 (P=0.02), day 14 (P=0.01), day 30 (P<0.0001), day 60 (P<0.0001) and day 90 (P<0.0001). When comparing CFB-G1 and CFB-G2, no significant differences were observed. Importantly, no changes were observed in the WOMAC and MPQ scores within the placebo group. Conclusion: Both CFB groups showed early and significantly improved levels of knee comfort. Knee comfort continued to significantly improve throughout the duration of this 90-day study. No significant differences were observed between the once-daily and the twice–daily doses of CFB.

Effect of Subetta on glycemic control in patients with type 2 diabetes mellitus: results of a multicenter, double-blind, placebo-controlled, randomized clinical study

Pharmateca ◽  
2020 ◽  
Vol 12_2020 ◽  
pp. 38-48
Author(s):  
A.M. Mkrtumyan Mkrtumyan ◽  
S.V. Vorobyev Vorobyev ◽  
A.R. Volkova Volkova ◽  
N.V. Vorokhobina Vorokhobina ◽  
◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Study ◽  
Glycemic Control ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Randomized Clinical Study

A Double-blind, Placebo-controlled, Randomized Clinical Study of the Effects of Vardenafil on Human Nasal Patency

2008 ◽  
Vol 22 (3) ◽  
pp. 276-279 ◽  
Author(s):  
Erdinc Aydin ◽  
Evren Hizal ◽  
Ovsen Onay ◽  
Basak Ozgen ◽  
Baris Turhan ◽  
...  
Keyword(s):  
Clinical Study ◽  
Nasal Patency ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Randomized Clinical Study

scholarly journals Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study

2014 ◽  
pp. 895 ◽  
Author(s):  
Tania Reyes-Izquierdo ◽  
Ruby Argumedo ◽  
Michael Phelan ◽  
Robert Keller ◽  
Cynthia Shu ◽  
...  
Keyword(s):  
Clinical Study ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Term Efficacy ◽  
Calcium Fructoborate ◽  
Controlled Clinical Study

scholarly journals Short-Term Efficacy of Calcium Fructoborate on Subjects with Knee Discomfort: a Comparative, Double-Blind, Placebo-Controlled Clinical Study [Corrigendum]

2021 ◽  
Vol Volume 16 ◽  
pp. 203-204
Author(s):  
Zbigniew Pietrzkowski ◽  
Michael J Phelan ◽  
Robert Keller ◽  
Cynthia Shu ◽  
Ruby Argumedo ◽  
...  
Keyword(s):  
Clinical Study ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Term Efficacy ◽  
Calcium Fructoborate ◽  
Controlled Clinical Study
Sign in / Sign up

Export Citation Format

Share Document